We consider a tumour population the heterogeneity of which is defined in terms of two distinct subpopulations, say, HER2+ and HER2− subpopulations or cancer-promoting (CP) and non-cancer-promoting (NCP) subpopulations. This evidence concerns the gene ERBB2 and cancer.